Combination drugs for returning soft tissue sarcoma in young people
Treatments studied
Part of Cancer clinical trials.
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 30 years old
- Have a soft tissue sarcoma that has come back or is not responding to treatment
- Have disease that can be seen on scans or exams
- Be recovered from side effects of past treatments (like chemo or radiation)
- Have acceptable blood counts, kidney, and liver function
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Soft Tissue Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.